May / June 2021


How imaging is advancing management of dry AMD

Emerging modalities and deep learning are helping to expose an old foe in non-neovascular age-related macular degeneration: reticular pseudodrusen.

Imaging biomarkers and precision medicine

Advances in computational power, and machine learning and diagnostic systems are creating new opportunities for understanding disease mechanisms.

Where genetics, diet and drusen size intersect

A close look at research into how diet may reverse the effect of genetic susceptibility in drusen size progression in age-related macular degeneration.

Will biosimilars find their place in retina?

With patents expiring, an approval pending and legislation aimed at easing regulations, more biosimilars could be coming. But are retina specialists ready?


Clinical Trial Closeup

How THR-149 targets alternate pathway

The plasma kallikrein inhibitor is being investigated to treat diabetic macular edema that doesn’t respond to anti-VEGF therapy.

Coding Commentary

Clearing up E/M ‘clarifications’

The AMA issued new evaluation and management guidelines that can be hard to appreciate.

Editor's Page

Imaging Forum

Retinal sequelae of novel oncology drugs

Getting to the cause of blurred vision in a man with Erdheim-Chester disease.


Surgical Pearl Video

Pearls for epiretinal membrane peeling

Proper visualization and positioning are key to achieving a successful peel.

Uveitis Forum

Taking treatment beyond adalimumab

An update on biologic alternatives for ocular inflammatory disease when the approved agent just won’t cut it.